Thyroid cancer, recognized as the most prevalent endocrine malignancy and ranking ninth among cancers globally, poses a significant health challenge with its diverse subtypes ranging from the more treatable papillary thyroid carcinoma to the highly aggressive anaplastic thyroid carcinoma, each
Today, we’re thrilled to sit down with Ivan Kairatov, a renowned expert in biopharmaceuticals with a deep focus on technology and innovation in the industry. With extensive experience in research and development, Ivan has been at the forefront of advancing cancer treatments, particularly in the
What happens when a chronic disease like systemic lupus erythematosus (SLE) steals not just health, but the very essence of daily life from millions worldwide, leaving them to grapple with relentless pain, fatigue, and organ damage? For over 3.4 million people battling this autoimmune condition, a
The biopharmaceutical industry is undergoing a profound transformation this year, as financial strategies adapt to a landscape shaped by economic pressures and groundbreaking innovation. With venture capital tightening its grip on risk, mergers and acquisitions gaining momentum, and licensing deals
Colorectal cancer (CRC) stands as a formidable global health challenge, ranking as the third most common cancer and the second leading cause of cancer-related deaths worldwide, according to GLOBOCAN 2020 data with a 10.0% incidence rate and a 9.4% mortality rate. Within the complex landscape of
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research, development, and innovation has positioned him as a thought leader in the cell and gene therapy (CGT) industry. With a sharp focus on emerging technologies and strategic growth, Ivan
